SCAD : a Registry of Spontaneous Coronary Artery Dissection
SCAD
A Registry of Spontaneous Coronary Artery Dissection
1 other identifier
observational
1,500
24 countries
73
Brief Summary
Spontaneous coronary artery dissection (SCAD) is an increasingly recognised cause of non-atherosclerotic acute coronary syndromes (ACS), predominantly afflicting young women without conventional atherosclerotic risk factors. Knowledge of SCAD has advanced considerably in the last few years as a result of data from a number of local and national registries 1-6. Like all rarer diseases however, a better understanding of SCAD will require international collaboration. At present, there is no European or International SCAD registry despite increasing recognition that there are key differences in the diagnosis, interventional and medical management of SCAD compared with conventional atherosclerotic ACS. The ESC-ACCA Study Group on Spontaneous Coronary Artery Dissection supported by the European Observational Research Programme will now build the first pan-European SCAD registry to advance our understanding of current management of this condition, inform guidelines, educate clinical colleagues and advance research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Longer than P75 for all trials
73 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 15, 2020
CompletedStudy Start
First participant enrolled
January 30, 2021
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2027
October 29, 2024
October 1, 2024
5.7 years
October 15, 2020
October 28, 2024
Conditions
Outcome Measures
Primary Outcomes (7)
Patient Status:
* Measure: Functional health status and clinical condition during follow-up. * Unit of Measure: Categorized as stable, improved, or worsened.
Up to 5 years post-enrollment
Vital Signs:
-Heart Rate: Measure: Heart rate monitoring. Unit of Measure: Beats per minute (bpm). -Blood Pressure: Measure: Systolic and diastolic blood pressure measurement. Unit of Measure: Millimeters of mercury (mmHg). -Oxygen Saturation: Measure: Oxygen saturation monitoring. Unit of Measure: Percentage (%).
Up to 5 years post-enrollment
Recurrent SCAD Events:
* Measure: Documentation of recurrent SCAD events, including clinical presentation, diagnosis, management, and procedures. * Unit of Measure: Number of recurrent SCAD events.
Up to 5 years post-enrollment
Imagery:
* Measure: Coronary angiography anonymized and sent for central review (Corelab) for confirmation and analysis. * Unit of Measure: Yes/No (whether imagery was obtained and sent).
Up to 5 years post-enrollment
Medications:
Antiplatelet Medications: * Measure: Use of antiplatelet medications during follow-up. Unit of Measure: Number of antiplatelet medications prescribed. * Beta-Blockers: Measure: Use of beta-blocker medications during follow-up. Unit of Measure: Number of beta-blockers prescribed. -ACE Inhibitors/ARBs: Measure: Use of ACE inhibitors or angiotensin receptor blockers (ARBs) during follow-up. Unit of Measure: Number of ACE inhibitors/ARBs prescribed. -Calcium Channel Blockers: Measure: Use of calcium channel blockers during follow-up. Unit of Measure: Number of calcium channel blockers prescribed. -Statins: Measure: Use of statin medications during follow-up. Unit of Measure: Number of statins prescribed. -Other Medications (if applicable): Measure: Use of other medication classes during follow-up. Unit of Measure: Number and type of additional medications prescribed.
Up to 5 years post-enrollment
Menstrual, Contraceptive, and Obstetric History:
* Measure: Menstrual status, use of contraceptives, and obstetric history during follow-up. * Unit of Measure: Categorical variables (e.g., premenopausal, postmenopausal; use of contraceptives: Yes/No).
Up to 5 years post-enrollment
Discharge Information:
* Measure: Discharge status following SCAD-related hospital admissions. * Unit of Measure: Categorical variables (e.g., discharged to home, transferred to rehabilitation).
Up to 5 years post-enrollment
Secondary Outcomes (7)
Procedures:
Up to 5 years post-enrollment
Other Coronary Vascular Events:
Up to 5 years post-enrollment
Symptomatology:
Up to 5 years post-enrollment
Pregnancy and Hormonal Therapy (when applicable):
Up to 5 years post-enrollment
Exercise History:
Up to 5 years post-enrollment
- +2 more secondary outcomes
Study Arms (2)
Retrospective
There are no interventions as the study is purely observational.
Prospective
There are no interventions as the study is purely observational.
Interventions
There are no interventions as the study is purely observational.
Eligibility Criteria
Patient aged 18 years and over with SCAD clinical diagnosis within the past 10 years and available coronary angiographic imagery.
You may qualify if:
- Patient having signed an Informed Consent
- Patient aged 18 years and over
- SCAD clinical diagnosis within the past 10 years and available coronary angiographic imagery
You may not qualify if:
- Patient unwilling or unable to consent
- Patients with iatrogenic or atherosclerotic coronary dissection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (73)
ICBA - Instituto Cardiovascular de Buenos Aires
Buenos Aires, Argentina
Medical University of Innsbruck, Internal Medicine III
Innsbruck, Austria
Klinik Landstrasse
Vienna, Austria
Klinik Ottakring
Vienna, Austria
Medical University of Vienna
Vienna, Austria
Landesklinikum Wiener Neustadt
Wiener Neustadt, Austria
AZ Sint jan, current president of Belgian ACCA
Bruges, Belgium
Cliniques Universitaires Saint-Luc (UCL)
Brussels, Belgium
Universitair Ziekenhuis Brussels
Brussels, Belgium
Antwerp University Hospital
Edegem, Belgium
Ziekenhuis Oost Limburg, Interventional cardiology/Coronary Care
Genk, Belgium
AZ Sint Lucas hospital
Ghent, Belgium
Ghent University Hospital
Ghent, Belgium
University Hospitals Leuven
Leuven, Belgium
CHR La Citadelle
Liège, Belgium
Les cliniques Saint Pierre
Ottignies, Belgium
AZ Delta
Roeselare, Belgium
AZ Nikolaas
Sint-Niklaas, Belgium
Clinical Center University of Sarajevo
Sarajevo, Bosnia and Herzegovina
Hospital Israelita Albert Einstein
São Paulo, Brazil
Instituto do Coração do HCFMUSP
São Paulo, Brazil
Universidade Federal de São Paulo (UNIFESP)
São Paulo, Brazil
University Hospital of Split (KBC Split)
Split, Croatia
Nicosia General Hospital
Nicosia, Cyprus
Nemocnice Pardubického kraje
Pardubice, Czechia
Hospital Na Homolce
Prague, Czechia
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Herlev and Gentofte Hospital
Hellerup, Denmark
Odense University Hospital
Odense, Denmark
CHRU Jean Minjoz
Besançon, France
Gabriel Montpied Hospital - CHU Clermont-Ferrand
Clermont-Ferrand, France
Hôpital de Chartres Louis Pasteur
Le Coudray, France
Cardiovascular Hospital Louis Pradel - Hospices Civils de Lyon
Lyon, France
Hôpital Jacques Cartier
Massy, France
Hôpital Cardiologique du Haut Lévêque - Bordeaux University
Pessac, France
Schüchtermann-Klinik Bad Rothenfelde
Bad Rothenfelde, Germany
Vivantes Klinikum in Friedrichshain
Berlin, Germany
University Heart and Vascular Center Hamburg Eppendorf
Hamburg, Germany
Robert Bosch Hospital
Stuttgart, Germany
Sotiria Thoracic Diseases Hospital
Athens, Greece
General Hospital of Kozani
Kozani, Greece
Tehran Heart Center
Tehran, Iran
Papa Giovanni XXIII Azienda Ospedaliera
Bergamo, Italy
Policlinico Riuniti Foggia
Foggia, Italy
Ospedale Policlinico San Martino IRCCS, Genova & Università di Genova
Genoa, Italy
Presidio Ospedaliero Carlo Poma
Mantova, Italy
ASST Grande Ospedale Niguarda
Milan, Italy
Centro Cardiologico Monzino, IRCCS
Milan, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
Noordwest Ziekenhuisgroep / NorthWest Clinics
Alkmaar, Netherlands
Amphia Hospital
Breda, Netherlands
Radboud University Medical Centre
Nijmegen, Netherlands
Auckland City Hospital - Green Lane Cardiovascular Service
Auckland, New Zealand
Haukeland University Hospital - Invasive cardiology
Bergen, Norway
Institute of Cardiology - Department of Interventional Cardiology and Angiology
Warsaw, Poland
Hospital Fernando Fonseca
Amadora, Portugal
Hospital de Braga
Braga, Portugal
Hospital do Espirito Santo de Evora
Evora, Portugal
Centro Hospitalar Tondela Viseu
Tondela, Portugal
University Hospital Centre Bezanijska Kosa
Belgrade, Serbia
Cardiology Clinic, UCC Nis
Niš, Serbia
National University Heart Centre Singapore
Singapore, Singapore
Stredoslovensky ustav srdcovych a cievnych chorob a.s
Banská Bystrica, Slovakia
Hospital Universitario de la Princesa
Madrid, Spain
William Harvey Hospital
Ashford, United Kingdom
Glan Clwyd Hospital
Bodelwyddan, United Kingdom
Bournemouth Hospital
Bournemouth, United Kingdom
Bristol Heart Institute
Bristol, United Kingdom
University Hospitals
Leicester, United Kingdom
Royal Brompton & Chelsea & Westminster Hospital
London, United Kingdom
Royal Free Hospital
London, United Kingdom
Related Links
MeSH Terms
Conditions
Study Officials
- STUDY DIRECTOR
Adham GHARIEB, PharmD
ESC
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 15, 2020
First Posted
September 19, 2024
Study Start
January 30, 2021
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
October 1, 2027
Last Updated
October 29, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share